Related Experiment Video
Updated: Apr 5, 2026

Bilateral Renal Ischemia-Reperfusion Model for Acute Kidney Injury in Mice
Published on: February 2, 2024
Urinary KIM-1 in children undergoing nephrotoxic antineoplastic treatment: a prospective cohort study
Danielle Carvalho Pedrosa1, Fernanda Macedo de Oliveira Neves1, Gdayllon Cavalcante Meneses2
1Medical Sciences Post-graduate Program, Department of Clinical Medicine, Universidade Federal do Ceará, Avenue Abolição, 4043, Fortaleza, Ceará, Brazil.
Background:
Acute kidney injury (AKI) is a significant complication in patients with cancer, and nephrotoxic drugs are among the most common causes of AKI. To date, there is no study evaluating the potential role of renal biomarkers in children receiving nephrotoxic chemotherapy.
Methods:
A prospective study was conducted in children receiving methotrexate (MTX) or platinum-based treatment. Urinary kidney injury molecule-1 (KIM-1) was measured 24 h after the initiation of the chemotherapy infusion, and serum creatinine (sCr) was measured prior to drug infusion and at 24, 48, 72, and 96 h, 1 and 2 weeks, and 3 months post-initiation of treatment.
Results:
A total of 64 children were evaluated, of whom 21 (32.8%) developed AKI. The majority had AKI stage 1 (n = 12, 57.1%) and only one developed AKI stage 3. Median values of urinary KIM-1 were higher in patients with AKI than in those without AKI [10.7, interquartile range (IQR) 1.6-17.9 vs. 4.3 (IQR 1.3-6.1) ng/mg creatinine; p < 0.01]. Urinary KIM-1 showed good discrimination for AKI in patients receiving nephrotoxic chemotherapy, with an area under the receiver operator characteristic curve for AKI up to 1 week later of 0.82 (95% confidence interval 0.66-0.95). Even when measured only 24 h after drug infusion, urinary KIM-1 still showed good discrimination to predict persistent renal impairment three months later.
Conclusion:
Urinary KIM-1 measured 24 h after the start of drug infusion has the potential to detect early AKI in pediatric patients treated with MTX or platinum-class drugs.
Insights
Urinary kidney injury molecule-1 (KIM-1) can detect acute kidney injury (AKI) early in children receiving chemotherapy. This renal biomarker shows potential for identifying nephrotoxic treatment complications in pediatric cancer patients.
Area of Science:
- Pediatric Nephrology
- Oncology
- Biomarker Research
Background:
- Acute kidney injury (AKI) is a common and serious complication in pediatric cancer patients, often caused by nephrotoxic chemotherapy.
- Current diagnostic methods for AKI may not be sensitive enough for early detection in this vulnerable population.
- There is a lack of research on renal biomarkers for monitoring AKI in children undergoing chemotherapy.
Purpose of the Study:
- To evaluate the potential of urinary kidney injury molecule-1 (KIM-1) as an early biomarker for acute kidney injury (AKI) in children receiving nephrotoxic chemotherapy.
- To assess the ability of urinary KIM-1 to predict persistent renal impairment following chemotherapy treatment.
Main Methods:
- A prospective study involving pediatric patients treated with methotrexate (MTX) or platinum-based chemotherapy.
- Urinary KIM-1 levels were measured 24 hours post-chemotherapy initiation.
- Serum creatinine (sCr) was monitored at multiple time points before and after treatment.
Main Results:
- 21 out of 64 children (32.8%) developed AKI, predominantly stage 1.
- Median urinary KIM-1 levels were significantly higher in children with AKI compared to those without (p < 0.01).
- Urinary KIM-1 demonstrated good discrimination for AKI (AUC 0.82) and predicted persistent renal impairment up to three months later.
Conclusions:
- Urinary KIM-1, measured 24 hours after chemotherapy initiation, shows promise for early AKI detection in pediatric patients.
- This biomarker can help identify children at risk of developing acute kidney injury from MTX or platinum-class drugs.
- Urinary KIM-1 may aid in the timely management of nephrotoxicity in pediatric cancer treatment.
Related Concept Videos
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Kidney Transplant II: Surgical Procedure
Pharmacokinetics in Pediatric Patients: Drug Excretion
Kidney Transplant III: Nursing Management
Acute Kidney Injury V: Interprofessional Care
Acute Kidney Injury I: Introduction

